FDA reviewer: Teva's studies fail to support expanded Parkinson's use for Azilect
This article was originally published in Scrip
Executive Summary
There is no demonstrated benefit of Teva's Azilect (rasagiline) for slowing the rate of progression of Parkinson's disease, a US FDA drug reviewer said, insisting that the company's data were "not robust" enough to support such a claim.